comparemela.com

Latest Breaking News On - Colleen hussey - Page 6 : comparemela.com

Moderna, Inc : Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform

Moderna's first bivalent booster vaccine candidate, mRNA-1273.211, demonstrated superior neutralizing titers compared to mRNA-1273 against all variants of concern, including Omicron; superiority was maintained

United kingdomLavina talukdarColleen husseyExchange commissionResearch squareCorporate communicationsModerna incChief executive officerNorthern hemispherePrivate securities litigation reform actAnnual reportVice president

Jorge Gomez Joins Moderna as Chief Financial Officer

Press release content from Accesswire. The AP news staff was not involved in its creation.

New yorkUnited statesUnited kingdomJorge gomezLavina talukdarDavid melineDentsply sironaColleen husseyNational university of colombiaPrior to cardinal healthUniversity of hartfordModerna executive committeeXylem incExchange commissionMaster of business administrationCorporate communications

Jorge Gomez Joins Moderna as C - GuruFocus com

GuruFocus Article or News written by ACCESSWIRE and the topic is about:

New yorkUnited statesUnited kingdomJorge gomezLavina talukdarDavid melineDentsply sironaColleen husseyNational university of colombiaPrior to cardinal healthUniversity of hartfordModerna executive committeeXylem incExchange commissionMaster of business administrationCorporate communications

Moderna, Inc : Jorge Gomez Joins Moderna as Chief Financial Officer

CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (Nasdaq:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join Moderna

New yorkUnited statesUnited kingdomJorge gomezLavina talukdarDavid melineDentsply sironaColleen husseyNational university of colombiaPrior to cardinal healthUniversity of hartfordModerna executive committeeXylem incExchange commissionMaster of business administrationCorporate communications

Moderna, Inc : Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint

Two 25 μg doses of mRNA-1273 in participants 6 months to under 6 years met primary endpoint with robust neutralizing antibody titers similar to adults mRNA-1273 was generally well tolerated in this age

United kingdomLavina talukdarColleen husseyExchange commissionCorporate communicationsEuropean medicines agencyModerna incDrug administrationChief executive officerVaccine adverse event reporting systemPrivate securities litigation reform actAnnual reportVice president

vimarsana © 2020. All Rights Reserved.